SCHEMBL8003243

SCHEMBL8003243

Cn1c(-c2ccccn2)nc(-c2ccc(C(C)(C)O)c(F)c2)c1Sc1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.59
GRM5 P41594 4/20 0.41
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
RAB9A P51151 1/20 0.36
PSD A5PKW4 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
GAA P10253 1/20 0.35
PPP1CA P62136 1/20 0.35
F10 P00742 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
HTT P42858 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8005772 0.91 FAAH (0.61) FAAHGRM5KDM4EALDH1A1RAB9A
SCHEMBL8005304 0.85 FAAH (0.65) FAAHGRM5KDM4EALDH1A1PSD
SCHEMBL7993064 0.83 FAAH (0.76) FAAHGRM5KDM4EALDH1A1RAB9A
SCHEMBL1304088 0.83 FAAH (0.69) FAAHGRM5PSDSMN1; SMN2LMNA
SCHEMBL1303197 0.81 FAAH (0.69) FAAHGRM5KDM4EALDH1A1RAB9A
SCHEMBL8008516 0.80 FAAH (0.71) FAAHGRM5KDM4EALDH1A1NPSR1
SCHEMBL1303133 0.79 FAAH (0.69) FAAHGRM5KDM4EALDH1A1RAB9A
SCHEMBL1303678 0.79 FAAH (0.69) FAAHGRM5KDM4EALDH1A1RAB9A
SCHEMBL8005193 0.79 FAAH (0.58) FAAHGRM5KDM4EALDH1A1NPSR1
SCHEMBL7993150 0.79 FAAH (0.54) FAAHGRM5KDM4EALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-8455528-B2 Imidazole derivatives useful as inhibitors of FAAH MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-11-03 US disclosed
WO-2009152025-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK & CO., INC. (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269769-A1 IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, HNMT FAAH 1/4885GRM5 786/4885KDM4E 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.